n-Methylpyrrolidone (NMP); Regulation Under the Toxic Substances Control Act (TSCA)
EPA proposes to regulate n-methylpyrrolidone (NMP) under TSCA due to unreasonable health risks. Med-spas using NMP-containing products (e.g., certain adhesives, solvents) must assess exposure and potentially switch to safer alternatives.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Med-spas using products containing NMP (e.g., some lash adhesives, nail products, or cleaning solvents). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends August 13, 2024; final rule expected within 1-2 years.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
EPA proposes to ban or restrict NMP in certain consumer and commercial products, requiring risk evaluation and possible substitution.
Who it affects
Med-spas using products containing NMP (e.g., some lash adhesives, nail products, or cleaning solvents).
What you must do
Identify any NMP-containing products used in your facility and prepare to phase them out or implement strict exposure controls.
Deadline
Comment period ends August 13, 2024; final rule expected within 1-2 years.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication